Down 3.1% today, more than its medical device peers' 2.0%; no story names it yet.
Fell on Nov 3
Down 8% on Nov 3, and still 4% under its Nov 2 close.
“Revenue decreased 7.9% to $206.7 million, driven primarily by a decline in U.S. revenue.”
INSP's Quality Score fell 2 points on Tue, Nov 10, to 4. It closed away from its high of the day (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2023 high | Down 80% |
| Latest filing | 8-K, Nov 2 |
TodayNo story names it yet.
Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.
After its last 4 reports it closed -2.4% on average, higher 1 of 4 times.
Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. INSP scores 4 today, against a median of 8.5 over its last 20 recorded sessions.
INSP is #48 of 84 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 48 |
Expected to report Wed Feb 10, after the close (in 92 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $206.7M, 8% less than a year ago; a loss of $0.84 a share, from a profit of $0.34.
“Revenue decreased 7.9% to $206.7 million, driven primarily by a decline in U.S. revenue.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| United States | $197M | $187M | $214M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 2)
| Measure | Figure |
|---|---|
| Capital expenditures | $35M to $40M |
“Operating expenses increased $23.5 million, or 12.8%, to $206.6 million, primarily due to $24.1 million of restructuring charges, legal settlement expense of $7.0 million, and higher legal fees, partially offset by lower marketing expenses and lower stock-based compensation expense.”
From its results filing (SEC filing · Nov 2)
Sales grew 51% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.7% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 2, 2026 | -3.2% | -7.9% | -4.3% |
| Aug 3, 2026 | +22.9% | +22.8% | +14.4% |
| May 4, 2026 | -14.3% | -12.0% | -20.9% |
Sales grew every year from 2018 to 2025, to $912M. It made a profit in two of the eight years.
RSI 37.9, MACD below signal, below its 50-day, above its 200-day. Not scored.
2 insiders sold $172K across 2 filings in the last 6 months. No open-market buys on record. The newest:
4 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: INSP is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
“While we are second-line to PAP therapies, there remains some competition with PAP therapies as sleep physicians often remain committed to prescribing PAP despite poor patient adherence to therapy.”
INSP scores 4 today, which Breakaway calls Below Average. It is #48 of 84 in Medical Devices by Quality Score, with 2 of 14 chart checks firing. Down 8% on Nov 3, and still 4% under its Nov 2 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
INSP scores 4 today, which Breakaway calls Below Average (0 to 5). That is #48 of 84 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind INSP's 4.
2 insiders sold $172K across 2 filings in the last 6 months. No open-market buys on record. The newest is Jason P. Kelly, Insider, who sold $57K on Aug 7. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.